Binchuan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Binchuan Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Huan Wei
Department of Neurosurgery, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, 646000 Luzhou, Sichuan, China
1 shared publication - Jie Yang
Department of Neurosurgery, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, 646000 Luzhou, Sichuan, China
1 shared publication - Jinyu Wang
Department of Neurosurgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, China, swmu.edu.cn
1 shared publication - Lishang Liao
Department of Neurosurgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
1 shared publication - Mingwei Zhang
Department of Neurosurgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
1 shared publication - Qi Liu
Department of Neurosurgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, China, swmu.edu.cn
1 shared publication
Latest Publications
- Open Access
- 28 February 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (3) , 45499
The Mechanism of PANoptosis in Alzheimer’s Disease: Exploring the Multiple Network Regulation of Cell Death
Alzheimer’s disease (AD) is a neurodegenerative disorder primarily affecting the geriatric population, characterized by progressive cognitive impairment and behavioral abnormalities. Due to the absence of effective disease-modifying therapies, AD imposes a substantial burden on patients and their families. The etiology and pathogenesis of AD have not been fully elucidated; multiple pathological alterations have been implicated, including the deposition of β-amyloid (Aβ) plaques, abnormal tau phosphorylation, and neuroinflammatory responses. These pathological changes contribute to neuronal damage, synaptic dysfunction, and neuronal death, ultimately leading to brain atrophy. Recent studies have identified PANoptosis as a critical regulatory mechanism of programmed cell death that influences the pathological progression of AD through multiple pathways, including modulation of Aβ plaque deposition and regulating neuroinflammatory responses. However, the precise mechanisms of these effects remain unclear. This review aims to comprehensively analyze recent research findings, focusing on the regulatory role of PANoptosis in AD, exploring the specific manifestations of the intricate network of cell death regulation in AD pathogenesis. By providing a systematic overview of emerging findings, this review offers new insights into the pathogenesis of AD and highlights potential directions for the development of targeted therapeutic strategies.
- 28 February 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (3) , 45499
Open AccessThe Mechanism of PANoptosis in Alzheimer’s Disease: Exploring the Multiple Network Regulation of Cell Death
Alzheimer’s disease (AD) is a neurodegenerative disorder primarily affecting the geriatric population, characterized by progressive cognitive impairment and behavioral abnormalities. Due to the absence of effective disease-modifying therapies, AD imposes a substantial burden on patients and their families. The etiology and pathogenesis of AD have not been fully elucidated; multiple pathological alterations have been implicated, including the deposition of β-amyloid (Aβ) plaques, abnormal tau phosphorylation, and neuroinflammatory responses. These pathological changes contribute to neuronal damage, synaptic dysfunction, and neuronal death, ultimately leading to brain atrophy. Recent studies have identified PANoptosis as a critical regulatory mechanism of programmed cell death that influences the pathological progression of AD through multiple pathways, including modulation of Aβ plaque deposition and regulating neuroinflammatory responses. However, the precise mechanisms of these effects remain unclear. This review aims to comprehensively analyze recent research findings, focusing on the regulatory role of PANoptosis in AD, exploring the specific manifestations of the intricate network of cell death regulation in AD pathogenesis. By providing a systematic overview of emerging findings, this review offers new insights into the pathogenesis of AD and highlights potential directions for the development of targeted therapeutic strategies.
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , e8871660
Ziziphus jujuba Mill. Suspension Ameliorates Scopolamine‐Induced Cognitive Impairment via PTGS2‐Centered Neuroinflammatory Signaling
Background: Cognitive impairment is a common feature of neurodegenerative diseases, in which sustained neuroinflammation critically contributes to neuronal dysfunction and memory decline. As a representative condition, Alzheimer’s disease (AD) provides key insights into inflammation‐associated cognitive impairment. However, current anti‐inflammatory interventions exhibit limited efficacy and potential adverse effects, highlighting the need for safer strategies targeting neuroinflammation‐related cognitive dysfunction. Objective: Guided by the concept of food–medicine homology, this study aimed to elucidate the molecular mechanisms by which Ziziphus jujuba alleviates cognitive impairment associated with neuroinflammation. Methods: AD‐relevant targets associated with cognitive dysfunction were obtained from Gene Expression Omnibus (GEO) and GeneCards, and active compounds of Z. jujuba were retrieved from traditional Chinese medicine systems pharmacology (TCMSP). Shared targets were prioritized using least absolute shrinkage and selection operator (LASSO), random forest (RF), and support vector machine (SVM) algorithms. The diagnostic value of the core target was evaluated by receiver operating characteristic (ROC) analysis and a nomogram model with calibration and decision curve analysis (DCA). Functional enrichment, localization analyses, and molecular docking were performed. Experimental validation was conducted in a scopolamine‐induced cognitive impairment mouse model using the Morris water maze (MWM), histopathology, and western blotting. Results: PTGS2 was identified as a key inflammatory target associated with neuroinflammation‐related cognitive impairment and was enriched in the NOD‐like receptor (NLR) signaling pathway. ROC and nomogram analyses indicated good diagnostic and predictive performance (area under the curve [AUC] > 0.7). PTGS2 was localized on chromosome 1 and showed relatively high expression in the cerebral cortex. Z. jujuba compounds exhibited strong binding to PTGS2 (ΔG ≤ −8.0 kcal/mol). In vivo, Z. jujuba improved cognitive performance, alleviated hippocampal injury, and downregulated PTGS2 and related inflammatory signaling pathways, including NLRP3/NF‐κB/MAPK and interleukin (IL)‐1β. Conclusion: This study demonstrates that Z. jujuba ameliorates neuroinflammation‐related cognitive dysfunction primarily by suppressing PTGS2‐centered inflammatory signaling. Integrating computational analyses and in vivo validation in scopolamine‐induced mice, our findings support Z. jujuba as a safe multitarget intervention for inflammation‐associated cognitive impairment and highlight the potential of food–medicine homology in neuroinflammatory cognitive disorders.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , e8871660
Open AccessZiziphus jujuba Mill. Suspension Ameliorates Scopolamine‐Induced Cognitive Impairment via PTGS2‐Centered Neuroinflammatory Signaling
Background: Cognitive impairment is a common feature of neurodegenerative diseases, in which sustained neuroinflammation critically contributes to neuronal dysfunction and memory decline. As a representative condition, Alzheimer’s disease (AD) provides key insights into inflammation‐associated cognitive impairment. However, current anti‐inflammatory interventions exhibit limited efficacy and potential adverse effects, highlighting the need for safer strategies targeting neuroinflammation‐related cognitive dysfunction. Objective: Guided by the concept of food–medicine homology, this study aimed to elucidate the molecular mechanisms by which Ziziphus jujuba alleviates cognitive impairment associated with neuroinflammation. Methods: AD‐relevant targets associated with cognitive dysfunction were obtained from Gene Expression Omnibus (GEO) and GeneCards, and active compounds of Z. jujuba were retrieved from traditional Chinese medicine systems pharmacology (TCMSP). Shared targets were prioritized using least absolute shrinkage and selection operator (LASSO), random forest (RF), and support vector machine (SVM) algorithms. The diagnostic value of the core target was evaluated by receiver operating characteristic (ROC) analysis and a nomogram model with calibration and decision curve analysis (DCA). Functional enrichment, localization analyses, and molecular docking were performed. Experimental validation was conducted in a scopolamine‐induced cognitive impairment mouse model using the Morris water maze (MWM), histopathology, and western blotting. Results: PTGS2 was identified as a key inflammatory target associated with neuroinflammation‐related cognitive impairment and was enriched in the NOD‐like receptor (NLR) signaling pathway. ROC and nomogram analyses indicated good diagnostic and predictive performance (area under the curve [AUC] > 0.7). PTGS2 was localized on chromosome 1 and showed relatively high expression in the cerebral cortex. Z. jujuba compounds exhibited strong binding to PTGS2 (ΔG ≤ −8.0 kcal/mol). In vivo, Z. jujuba improved cognitive performance, alleviated hippocampal injury, and downregulated PTGS2 and related inflammatory signaling pathways, including NLRP3/NF‐κB/MAPK and interleukin (IL)‐1β. Conclusion: This study demonstrates that Z. jujuba ameliorates neuroinflammation‐related cognitive dysfunction primarily by suppressing PTGS2‐centered inflammatory signaling. Integrating computational analyses and in vivo validation in scopolamine‐induced mice, our findings support Z. jujuba as a safe multitarget intervention for inflammation‐associated cognitive impairment and highlight the potential of food–medicine homology in neuroinflammatory cognitive disorders.